Grand Pharmaceutical Group (DB:MX6A) - Hisse Senedi Fiyatı, Haberler ve Analizler

MX6A Stoklara Genel Bakış

MX6A temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	2/6
Finansal Sağlık	6/6
Temettüler	4/6

Ödüller

Adil değer tahminimizden 60.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 2.29% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 12.9% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Grand Pharmaceutical Group Limited Rakipler

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€304.6m

Pierrel

DB:2FJ0

€92.8m

Merck KGaA

XTRA:MRK

€61.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Grand Pharmaceutical Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$0.53
52 Haftanın En Yüksek Seviyesi	HK$0.62
52 Haftanın En Düşük Seviyesi	HK$0.38
Beta	0.73
11 Aylık Değişim	0%
3 Aylık Değişim	8.02%
1 Yıllık Değişim	0%
33 Yıllık Değişim	-22.79%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-25.85%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MX6A	DE Pharmaceuticals	DE Pazar
7D	1.9%	1.6%	1.1%
1Y	0%	-19.0%	7.2%

Getiri vs. Endüstri: MX6A geçen yıl % -19 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: MX6A geçen yıl % 7.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MX6A's price volatile compared to industry and market?
MX6A volatility
MX6A Average Weekly Movement	12.4%
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: MX6A hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MX6A 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1995	10,775	Chao Zhou	www.grandpharm.com

Bir yatırım holding şirketi olan Grand Pharmaceutical Group Limited, farmasötik preparatlar ve tıbbi cihazlar, biyoteknoloji ve sağlık ürünleri ve farmasötik hammaddelerin araştırılması ve geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, solunum, oftalmoloji, serebro-kardiyovasküler acil ve biyoteknoloji ile ilgili ürünler sunmaktadır. Farmasötik, taurin, zirai kimyasallar, kimyasal ilaç ve amino asit serisi ürünler üretmekte ve satmaktadır.

Grand Pharmaceutical Group Limited Temel Bilgiler Özeti

Grand Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MX6A temel i̇stati̇sti̇kler
Piyasa değeri	€1.94b
Kazançlar(TTM)	€293.19m
Gelir(TTM)	€1.29b

6.6x

F/K Oranı

1.5x

P/S Oranı

MX6A aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MX6A gelir tablosu (TTM)
Gelir	HK$10.59b
Gelir Maliyeti	HK$4.34b
Brüt Kâr	HK$6.25b
Diğer Giderler	HK$3.84b
Kazançlar	HK$2.41b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.69
Brüt Marj	59.00%
Net Kâr Marjı	22.75%
Borç/Özkaynak Oranı	28.1%

MX6A uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

5.7%

Mevcut Temettü Verimi

38%

Ödeme Oranı

MX6A Stoklara Genel Bakış

Ödüller

Risk Analizi

Grand Pharmaceutical Group Limited Rakipler

XTRA:DMP

€2.0b

XTRA:PSG

€304.6m

DB:2FJ0

€92.8m

XTRA:MRK

€61.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

New minor risk - Share price stability

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

Recent updates

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

New minor risk - Share price stability

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought €44k worth of stock

Dividend of HK$0.26 announced

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022)

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.8% yield

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

First half 2022 earnings released: EPS: HK$0.20 (vs HK$0.34 in 1H 2021)

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Less than half of directors are independent

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Less than half of directors are independent

Executive Director recently bought €64k worth of stock

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 21% undervalued after recent price drop